Sofie Struyf

17.2k total citations · 3 hit papers
207 papers, 13.9k citations indexed

About

Sofie Struyf is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sofie Struyf has authored 207 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Oncology, 105 papers in Immunology and 56 papers in Molecular Biology. Recurrent topics in Sofie Struyf's work include Chemokine receptors and signaling (110 papers), Immunotherapy and Immune Responses (47 papers) and Cell Adhesion Molecules Research (42 papers). Sofie Struyf is often cited by papers focused on Chemokine receptors and signaling (110 papers), Immunotherapy and Immune Responses (47 papers) and Cell Adhesion Molecules Research (42 papers). Sofie Struyf collaborates with scholars based in Belgium, Saudi Arabia and Italy. Sofie Struyf's co-authors include Jo Van Damme, Paul Proost, Ghislain Opdenakker, Evemie Schutyser, Mieke Gouwy, Jo Vandercappellen, Dominique Schols, Erik De Clercq, Rik Janssens and Marc Parmentier and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Sofie Struyf

202 papers receiving 13.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation

2003 1.3k citations Sofie Struyf, Jo Van Damme et al. profile →
The CC chemokine CCL20 and its receptor CCR6

2003 644 citations Evemie Schutyser, Sofie Struyf et al. profile →
The role of CXC chemokines and their receptors in cancer

2008 520 citations Jo Vandercappellen, Jo Van Damme et al. profile →

Peers

Countries citing papers authored by Sofie Struyf

Since Specialization

Citations

This map shows the geographic impact of Sofie Struyf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Struyf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Struyf more than expected).

Fields of papers citing papers by Sofie Struyf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofie Struyf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Struyf. The network helps show where Sofie Struyf may publish in the future.

Co-authorship network of co-authors of Sofie Struyf

This figure shows the co-authorship network connecting the top 25 collaborators of Sofie Struyf. A scholar is included among the top collaborators of Sofie Struyf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofie Struyf. Sofie Struyf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dominant negative ADA2 mutations cause ADA2 deficiency in heterozygous carriers 2025 ·The Journal of Experimental Medicine ·(unknown), Lisa Ehlers, (unknown), (unknown), Selket Delafontaine, (unknown), (unknown), Rik Schrijvers, Petra De Haes, Sofie Struyf, Giorgia Bucciol, Yuval Itan, Alexandre Bolze, Arnout Voet, Anneleen Hombrouck, Leen Moens, Benson Ogunjimi, Isabelle Meyts	0
2	Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases 2024 ·Autoimmunity Reviews ·(unknown), (unknown), Sofie Struyf, Niels Hellings	6
3	Inhibiting CFTR through inh-172 in primary neutrophils reveals CFTR-specific functional defects 2024 ·Scientific Reports ·(unknown), Marfa Blanter, (unknown), Mieke Gouwy, Natalie Lorent, Mieke Boon, Sofie Struyf, Marianne Carlon	1
4	Antibodies as tools in cytokine discovery and usage for diagnosis and therapy of inflammatory diseases 2023 ·European Cytokine Network ·Jo Van Damme, Ghislain Opdenakker, (unknown), Sofie Struyf	2
5	Inhibition of renal fibrosis with a human CXCL9‐derived glycosaminoglycan‐binding peptide 2022 ·Clinical & Translational Immunology ·(unknown), Mohammad Ayodhia Soebadi, (unknown), (unknown), Mieke Metzemaekers, Nele Berghmans, Vincent Vanheule, Maarten Albersen, Ghislain Opdenakker, Jo Van Damme, Ben Sprangers, Paul Proost, Sofie Struyf	2
6	A stabilized CXCL9(74–103)-derived peptide selectively inhibits proliferation, adhesion and metastasis of tumor cells that express high levels of heparan sulfate 2022 ·International Journal of Biological Macromolecules ·(unknown), (unknown), Nele Berghmans, Sam Noppen, (unknown), (unknown), (unknown), Erik Martens, (unknown), Noëmie Pörtner, Dominique Schols, Paul Proost, Sofie Struyf	3
7	The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer 2021 ·Cancers ·(unknown), Jo Van Damme, Sofie Struyf	15
8	The Chemokine-Based Peptide, CXCL9(74-103), Inhibits Angiogenesis by Blocking Heparan Sulfate Proteoglycan-Mediated Signaling of Multiple Endothelial Growth Factors 2021 ·Cancers ·(unknown), (unknown), Nele Berghmans, Melissa García‐Caballero, (unknown), Noëmie Pörtner, Vincent Vanheule, (unknown), Mohammad Mairaj Siddiquei, Ahmed M. Abu El‐Asrar, Peter Carmeliet, Pieter Van Wielendaele, Ingrid De Meester, Jo Van Damme, Paul Proost, Sofie Struyf	15
9	Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS) 2020 ·International Journal of Molecular Sciences ·(unknown), Niels Hellings, Ghislain Opdenakker, Sofie Struyf	73
10	CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems 2020 ·Frontiers in Immunology ·(unknown), Paul J. Collins, Mieke Metzemaekers, Max Meyrath, Martyna Szpakowska, (unknown), Sofie Struyf, Paul Proost, Andy Chevigné, Daniel F. Legler, Matthias Eberl, Bernhard Moser	22
11	Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis 2011 ·European Journal of Ophthalmology ·Ahmed M. Abu El‐Asrar, Sofie Struyf, Dustan Kangave, Saleh A. Al‐Obeidan, Ghislain Opdenakker, Karel Geboes, Jo Van Damme	95
12	Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder? 2011 ·European Cytokine Network ·(unknown), Sofie Struyf, Ghislain Opdenakker, Silvano Sozzani, Jo Van Damme, Geneviève Laureys	17
13	Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4 2009 ·The Journal of Immunology ·Sofie Struyf, Sam Noppen, Tamara Loos, Anneleen Mortier, Mieke Gouwy, Hannelien Verbeke, Dana Huskens, Souphalone Luangsay, Marc Parmentier, Karel Geboes, Dominique Schols, Jo Van Damme, Paul Proost	76
14	Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation 2008 ·The Journal of Experimental Medicine ·Paul Proost, Tamara Loos, Anneleen Mortier, Evemie Schutyser, Mieke Gouwy, Sam Noppen, Chris Dillen, Isabelle Ronsse, René Conings, Sofie Struyf, Ghislain Opdenakker, Prabhat C. Maudgal, Jo Van Damme	149
15	Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration 2007 ·Blood ·Paul Proost, Anneleen Mortier, Tamara Loos, Jo Vandercappellen, Mieke Gouwy, Isabelle Ronsse, Evemie Schutyser, Willy Put, Marc Parmentier, Sofie Struyf, Jo Van Damme	113
16	Platelet Factor-4 Variant Chemokine CXCL4L1 Inhibits Melanoma and Lung Carcinoma Growth and Metastasis by Preventing Angiogenesis 2007 ·Cancer Research ·Sofie Struyf, Marie D. Burdick, Elke Peeters, (unknown), Chris Dillen, Paul Proost, Jo Van Damme, Robert M. Strieter	88
17	TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis 2006 ·Laboratory Investigation ·Tamara Loos, (unknown), Sofie Struyf, Evemie Schutyser, Klara Gijsbers, Mieke Gouwy, (unknown), Willy Put, Isabelle Ronsse, Bernard Grillet, Ghislain Opdenakker, Jo Van Damme, Paul Proost	101
18	Platelets Release CXCL4L1, a Nonallelic Variant of the Chemokine Platelet Factor-4/CXCL4 and Potent Inhibitor of Angiogenesis 2004 ·Circulation Research ·Sofie Struyf, Marie D. Burdick, Paul Proost, Jo Van Damme, Robert M. Strieter	126
19	Unique Regulation of CCL18 Production by Maturing Dendritic Cells 2003 ·The Journal of Immunology ·Marisa Vulcano, Sofie Struyf, Patrizia Scapini, Marco A. Cassatella, Sergio Bernasconi, Raffaella Bonecchi, Angelica Calleri, Giuseppe Penna, Luciano Adorini, Walter Luini, Alberto Mantovani, Jo Van Damme, Silvano Sozzani	127
20	Regulated Production and Molecular Diversity of Human Liver and Activation-Regulated Chemokine/Macrophage Inflammatory Protein-3α from Normal and Transformed Cells 2000 ·The Journal of Immunology ·Evemie Schutyser, Sofie Struyf, Patricia Menten, Jean‐Pierre Lenaerts, René Conings, Willy Put, Anja Wuyts, Paul Proost, Jo Van Damme	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact